A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer Meeting Abstract
| Authors: | Petrylak, D. P.; Perez, R. P.; Zhang, J.; Smith, D. C.; Ruether, J. D.; Sridhar, S. S.; Sangha, R. S.; Lang, J. M.; Heath, E. I.; Merchan, J. R.; Gartner, E. M.; Chu, R.; Anand, B.; Doñate, F.; Jackson, L.; Adams, J.; Melhem-Bertrandt, A.; Rosenberg, J. E. |
| Abstract Title: | A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 7s |
| Language: | English |
| ACCESSION: | WOS:000411895700015 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.106 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 106 -- Source: Wos |
